公开(公告)号：US5397696A

公开(公告)日：1995-03-14

申请号：US743518

申请日：1991-08-12

申请人： Richard Yanagihara ,  Vivek R. Nerurkar ,  Carol Jenkins ,  Mark Miller ,  Ralph M. Garruto

发明人： Richard Yanagihara ,  Vivek R. Nerurkar ,  Carol Jenkins ,  Mark Miller ,  Ralph M. Garruto

IPC分类号： A61K39/00 ,  C07K14/15 ,  C07K16/10 ,  C12N7/00 ,  C12N7/02

CPC分类号： C07K14/005 ,  C07K16/1036 ,  C12N7/00 ,  A61K39/00 ,  C12N2510/00 ,  C12N2740/14021 ,  C12N2740/14022

摘要： The present invention relates to a human T-cell line (PNG-1) persistently infected with a Papua New Guinea (PNG) HTLV-I variant and to the infecting virus (PNG-1 variant). Cells of the present invention express viral antigens, type C particles and have a low level of reverse transcriptase activity. The establishment of this cell line, the first of its kind from an individual from Papua New Guinea, makes possible the screening of Melanesian populations using a local virus strain. The present invention also relates to vaccines for use in humans against infection with and diseases caused by HTLV-I and related viruses. The invention further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-I and related viruses.

摘要翻译： 本发明涉及持续感染巴布亚新几内亚（PNG）HTLV-1变体和感染病毒（PNG-1变体）的人T细胞系（PNG-1）。 本发明的细胞表达病毒抗原，C型粒子并具有低水平的逆转录酶活性。 这种细胞系的建立是来自巴布亚新几内亚的第一种细胞系，使得可以使用当地病毒株筛选美拉尼西亚人群。 本发明还涉及用于人类针对感染的疫苗和由HTLV-1和相关病毒引起的疾病。 本发明还涉及用于检测和诊断由HTLV-1和相关病毒引起的感染和疾病的各种生物测定和试剂盒。